Guoyuan Securities (HK) analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$16.81.
InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$18.74.
Guoyuan Securities (HK) analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$16.81.
InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$18.74.
